Navigation Links
First all-African GM crop is resistant to maize streak virus
Date:8/15/2007

The first all-African genetically modified crop plant with resistance to the severe maize streak virus (MSV), which seriously reduces the continents maize yield, has been developed by scientists from the University of Cape Town and PANNAR PTY Ltd, a South African seed company. The research, published in Plant Biotechnology Journal represents a significant advance in African agricultural biotechnology, and will play an important role in alleviating Africas food shortages and famine.

Dr Dionne Shepherd, lead researcher explains, MSV is transmitted to maize by small insects called leafhoppers. The disease is therefore a result of a complex interplay between the plant, the virus and insect. Factors that can influence the severity of the disease include the age at which the plant is infected (the younger the plant, the more severe the infection), the maize variety (some are more susceptible than others), and environmental conditions.

We have created an MSV-resistant maize variety by genetic engineering, using an approach known as pathogen-derived resistance. This means that a gene from the viral pathogen is used to protect the plant from that pathogen. We mutated a viral gene that under normal circumstances produces a protein that is essential for the virus to replicate itself and inserted it into the maize plants genome, creating genetically modified maize. When the virus infects one of these transgenic maize plants, it displays a significant delay in symptom development, a decrease in symptom severity and higher survival rates than non-transgenic plants.

The next stage of the research involves field trials to ensure that the transformed crop is digestible, that the protein is not an allergen and that it will be ecologically friendly to other organisms within the environment. Following the results of these trials, the crop will be monitored over a number of growing seasons before it is made accessible to local farmers.


'/>"/>

Contact: Lucy Mansfield
lucy.mansfield@oxon.blackwellpublishing.com
44-186-547-6241
Blackwell Publishing Ltd.
Source:Eurekalert

Page: 1

Related biology news :

1. A genes first kiss sets off that affair known as puberty
2. Timing is everything: First step in protein building revealed
3. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
6. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
7. First real-time view of developing neurons reveals surprises, say Stanford researchers
8. Love at first smell
9. Worlds largest rainforest drying experiment completes first phase
10. PCRM develops worlds first cruelty-free insulin assay
11. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... April 20, 2017 For today, Stock-Callers.com ... novel drug development and clinical research aimed at treating diseases ... (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. ... ). You can access our complimentary research reports on these ... ...
(Date:4/19/2017)... , ... April 19, 2017 , ... Nobilis Therapeutics ... , Company Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder ... of an 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic ...
(Date:4/19/2017)... Calif. , April 19, 2017  As ... Drug Abuse and Heroin Summit ,  Proove┬« Biosciences, ... study analyzing genetics, environmental, and lifestyle factors to ... from the University of Southern California (USC), the ... , and Proove publish results showing that Proove ...
(Date:4/18/2017)... ... April 18, 2017 , ... CallTower, an ... Next-Gen Solution Provider. , Channel Partners program recognizes IT and telecom channel leaders ... and advocacy of the channel during transition and convergence. CallTower is the first ...
Breaking Biology Technology: